東華大學圖書館 |

Translational research methods for diabetes, obesity, and nonalcoholic fatty liver disease = a focus on early phase clinical drug development /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Translational research methods for diabetes, obesity, and nonalcoholic fatty liver disease/ edited by Andrew J. Krentz, Christian Weyer, Marcus Hompesch.
其他題名:	a focus on early phase clinical drug development /
其他作者:	Krentz, Andrew J.
出版者:	Cham :Springer International Publishing : : 2019.,
面頁冊數:	xi, 556 p. :ill., digital ;24 cm.
內容註:	Part 1: Review of Clinical Investigative Methods -- Chapter 1: Quantifying Insulin Action in Humans -- Chapter 2: Assessment of Islet Alpha- and Beta-Cell Function -- Chapter 3: Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins -- Chapter 4: Measurement of Energy Expenditure -- Chapter 5: QUANTIFYING APPETITE AND SATIETY -- Chapter 6: Non-invasive quantitative magnetic resonance imaging and spectroscopic biomarkers in nonalcoholic fatty liver disease and other cardiometabolic diseases associated with ectopic fat deposition -- Chapter 7: Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development -- Chapter 8: Positron emission tomography and computed tomography measurement of brown fat thermal activation: key tool for developing novel pharmacotherapeutics for obesity and diabetes -- Chapter 9: Isotopic Tracers for the Measurement of Metabolic Flux Rates -- Chapter 10: Role of Tissue Biopsy in Drug Development for NonAlcoholic Fatty Liver Disease and Other Metabolic Disorders -- Chapter 11: Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH -- Chapter 12: Omics: Potential role in early phase drug development -- Part 2: Preclinical Drug Development and Transitioning to Clinical Studies -- Chapter 13: Peptide Drug Design for Diabetes & Related Metabolic Diseases -- Chapter 14: ANIMAL MODELS OF TYPE 2 DIABETES, OBESITY AND NONALCOHOLIC STEATOHEPATITIS - CLINICAL TRANSLATABILITY AND APPLICABILITY IN PRECLINICAL DRUG DEVELOPMENT -- Chapter 15: Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c -- Chapter 16: Emerging Circulating Biomarkers For The Diagnosis And Assessment Of Treatment Responses In Patients With Hepatic Fat Accumulation, Nash And Liver Fibrosis -- Chapter 17: Quantitative Approaches in Translational Cardiometabolic Research: An Overview -- Chapter 18: Transitioning from Preclinical to Clinical Drug Development -- Chapter 19: Regulatory Considerations for Early Study and Clinical Development of Drugs for Diabetes, Obesity, NonAlcoholic Steatohepatitis (NASH) and other Cardiometabolic Disorders -- Chapter 20: Early Phase Metabolic Research with Reference to Special Populations.
Contained By:	Springer eBooks
標題:	Drug development - Research -
電子資源:	https://doi.org/10.1007/978-3-030-11748-1
ISBN:	9783030117481

Translational research methods for diabetes, obesity, and nonalcoholic fatty liver disease = a focus on early phase clinical drug development /
Translational research methods for diabetes, obesity, and nonalcoholic fatty liver diseasea focus on early phase clinical drug development /[electronic resource] :edited by Andrew J. Krentz, Christian Weyer, Marcus Hompesch. - 2nd ed. - Cham :Springer International Publishing :2019. - xi, 556 p. :ill., digital ;24 cm.

Part 1: Review of Clinical Investigative Methods -- Chapter 1: Quantifying Insulin Action in Humans -- Chapter 2: Assessment of Islet Alpha- and Beta-Cell Function -- Chapter 3: Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins -- Chapter 4: Measurement of Energy Expenditure -- Chapter 5: QUANTIFYING APPETITE AND SATIETY -- Chapter 6: Non-invasive quantitative magnetic resonance imaging and spectroscopic biomarkers in nonalcoholic fatty liver disease and other cardiometabolic diseases associated with ectopic fat deposition -- Chapter 7: Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development -- Chapter 8: Positron emission tomography and computed tomography measurement of brown fat thermal activation: key tool for developing novel pharmacotherapeutics for obesity and diabetes -- Chapter 9: Isotopic Tracers for the Measurement of Metabolic Flux Rates -- Chapter 10: Role of Tissue Biopsy in Drug Development for NonAlcoholic Fatty Liver Disease and Other Metabolic Disorders -- Chapter 11: Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH -- Chapter 12: Omics: Potential role in early phase drug development -- Part 2: Preclinical Drug Development and Transitioning to Clinical Studies -- Chapter 13: Peptide Drug Design for Diabetes & Related Metabolic Diseases -- Chapter 14: ANIMAL MODELS OF TYPE 2 DIABETES, OBESITY AND NONALCOHOLIC STEATOHEPATITIS - CLINICAL TRANSLATABILITY AND APPLICABILITY IN PRECLINICAL DRUG DEVELOPMENT -- Chapter 15: Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c -- Chapter 16: Emerging Circulating Biomarkers For The Diagnosis And Assessment Of Treatment Responses In Patients With Hepatic Fat Accumulation, Nash And Liver Fibrosis -- Chapter 17: Quantitative Approaches in Translational Cardiometabolic Research: An Overview -- Chapter 18: Transitioning from Preclinical to Clinical Drug Development -- Chapter 19: Regulatory Considerations for Early Study and Clinical Development of Drugs for Diabetes, Obesity, NonAlcoholic Steatohepatitis (NASH) and other Cardiometabolic Disorders -- Chapter 20: Early Phase Metabolic Research with Reference to Special Populations.

This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders. Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs. This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease is of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.

ISBN: 9783030117481

Standard No.: 10.1007/978-3-030-11748-1doiSubjects--Topical Terms:

3387068
Drug development
--Research

LC Class. No.: RM301.25

Dewey Class. No.: 615.19

Translational research methods for diabetes, obesity, and nonalcoholic fatty liver disease = a focus on early phase clinical drug development /
LDR:04637nmm a2200337 a 4500 001 2180735
003 DE-He213
005 20190402141311.0
006 m d
007 cr nn 008maaau
008 191122s2019 gw s 0 eng d
020 $a 9783030117481 $q (electronic bk.)
020 $a 9783030117474 $q (paper)
024 7 $a 10.1007/978-3-030-11748-1 $2 doi
035 $a 978-3-030-11748-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25
072 7 $a MJGD $2 bicssc
072 7 $a MED027000 $2 bisacsh
072 7 $a MJGD $2 thema
082 0 4 $a 615.19 $2 23
090 $a RM301.25 $b .T772 2019
245 0 0 $a Translational research methods for diabetes, obesity, and nonalcoholic fatty liver disease $h [electronic resource] : $b a focus on early phase clinical drug development / $c edited by Andrew J. Krentz, Christian Weyer, Marcus Hompesch.
250 $a 2nd ed.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a xi, 556 p. : $b ill., digital ; $c 24 cm.
505 0 $a Part 1: Review of Clinical Investigative Methods -- Chapter 1: Quantifying Insulin Action in Humans -- Chapter 2: Assessment of Islet Alpha- and Beta-Cell Function -- Chapter 3: Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins -- Chapter 4: Measurement of Energy Expenditure -- Chapter 5: QUANTIFYING APPETITE AND SATIETY -- Chapter 6: Non-invasive quantitative magnetic resonance imaging and spectroscopic biomarkers in nonalcoholic fatty liver disease and other cardiometabolic diseases associated with ectopic fat deposition -- Chapter 7: Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development -- Chapter 8: Positron emission tomography and computed tomography measurement of brown fat thermal activation: key tool for developing novel pharmacotherapeutics for obesity and diabetes -- Chapter 9: Isotopic Tracers for the Measurement of Metabolic Flux Rates -- Chapter 10: Role of Tissue Biopsy in Drug Development for NonAlcoholic Fatty Liver Disease and Other Metabolic Disorders -- Chapter 11: Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH -- Chapter 12: Omics: Potential role in early phase drug development -- Part 2: Preclinical Drug Development and Transitioning to Clinical Studies -- Chapter 13: Peptide Drug Design for Diabetes & Related Metabolic Diseases -- Chapter 14: ANIMAL MODELS OF TYPE 2 DIABETES, OBESITY AND NONALCOHOLIC STEATOHEPATITIS - CLINICAL TRANSLATABILITY AND APPLICABILITY IN PRECLINICAL DRUG DEVELOPMENT -- Chapter 15: Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c -- Chapter 16: Emerging Circulating Biomarkers For The Diagnosis And Assessment Of Treatment Responses In Patients With Hepatic Fat Accumulation, Nash And Liver Fibrosis -- Chapter 17: Quantitative Approaches in Translational Cardiometabolic Research: An Overview -- Chapter 18: Transitioning from Preclinical to Clinical Drug Development -- Chapter 19: Regulatory Considerations for Early Study and Clinical Development of Drugs for Diabetes, Obesity, NonAlcoholic Steatohepatitis (NASH) and other Cardiometabolic Disorders -- Chapter 20: Early Phase Metabolic Research with Reference to Special Populations.
520 $a This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders. Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs. This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease is of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.
650 0 $a Drug development $x Research $x Methodology. $3 3387068
650 0 $a Diabetes $x Research $x Methodology. $3 3387069
650 0 $a Obesity $x Research $x Methodology. $3 3387070
650 0 $a Fatty liver $x Research $x Methodology. $3 3387071
650 1 4 $a Diabetes. $3 544344
650 2 4 $a Metabolic Diseases. $3 895373
650 2 4 $a Pharmacology/Toxicology. $3 890953
700 1 $a Krentz, Andrew J. $3 842063
700 1 $a Weyer, Christian. $3 3387067
700 1 $a Hompesch, Marcus. $3 2132182
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u https://doi.org/10.1007/978-3-030-11748-1
950 $a Medicine (Springer-11650)